相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer et al.
SCIENCE (2020)
Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma
Tomohiro Aoki et al.
CANCER DISCOVERY (2020)
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Carlos A. Ramos et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4-and CD8-restricted epitopes as targets for T-cell immunotherapy
Mamta Kalra et al.
CYTOTHERAPY (2019)
Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma
Jakub Svoboda et al.
BLOOD (2018)
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma
Catherine M. Bollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
Christopher C. Kloss et al.
MOLECULAR THERAPY (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
Amina Dahmani et al.
CANCERS (2018)
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation
Lauren P. McLaughlin et al.
BLOOD (2018)
Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
Xingliang Guo et al.
FRONTIERS IN PHARMACOLOGY (2018)
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Chun-Meng Wang et al.
CLINICAL CANCER RESEARCH (2017)
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Carlos A. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
C. A. van der Weyden et al.
BLOOD CANCER JOURNAL (2017)
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
Marco Ruella et al.
CANCER DISCOVERY (2017)
HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?
Marcel Nijland et al.
ONCOIMMUNOLOGY (2017)
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma
Christopher D. Carey et al.
BLOOD (2017)
Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors
Si Li et al.
CLINICAL CANCER RESEARCH (2017)
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen et al.
BLOOD (2016)
Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma
Baoping Guo et al.
BMC MEDICINE (2016)
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Margaretha G. M. Roemer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Engineered T cells: the promise and challenges of cancer immunotherapy
Andrew D. Fesnak et al.
NATURE REVIEWS CANCER (2016)
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz et al.
LANCET (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Adoptive T Cell Immunotherapy for Cancer
Karlo Perica et al.
RAMBAM MAIMONIDES MEDICAL JOURNAL (2015)
Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
Catherine M. Bollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Macrophages and Dendritic Cells as Actors in the Immune Reaction of Classical Hodgkin Lymphoma
Christiane Silke Tudor et al.
PLOS ONE (2014)
Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)
Leo I. Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
Liza B. John et al.
ONCOIMMUNOLOGY (2013)
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation
Ekaterina Doubrovina et al.
BLOOD (2012)
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Michael R. Green et al.
CLINICAL CANCER RESEARCH (2012)
Hodgkin lymphoma
Ralf Küppers et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Flow Cytometric Analysis of CD123 is Useful for Immunophenotyping Classical Hodgkin Lymphoma
Jonathan R. Fromm
CYTOMETRY PART B-CLINICAL CYTOMETRY (2011)
Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment
Christian Steidl et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
Helen E. Heslop et al.
BLOOD (2010)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green et al.
BLOOD (2010)
Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
Andreas Engert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Christian Steidl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
Asad Bashey et al.
BLOOD (2009)
Circulating clonotypic B cells in classic Hodgkin lymphoma
Richard J. Jones et al.
BLOOD (2009)
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
Antonio Di Stasi et al.
BLOOD (2009)
PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
Ryo Yamamoto et al.
BLOOD (2008)
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor
Aaron E. Foster et al.
JOURNAL OF IMMUNOTHERAPY (2008)
HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma
Arjan Diepstra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege
Takashi Ishida et al.
CANCER RESEARCH (2006)
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group
RM Meyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
lHuman cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis
G Dotti et al.
BLOOD (2005)
The role of interleukin-3 in classical Hodgkin's disease
D Aldinucci et al.
LEUKEMIA & LYMPHOMA (2005)
Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease
CH Moskowitz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma
NA Marshall et al.
BLOOD (2004)
Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease
DM Burns et al.
BLOOD REVIEWS (2004)
Cytotoxic T lymphocyte therapy for Epstein-Barr virus Hodgkin's disease
CM Bollard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease
CM Bollard et al.
JOURNAL OF IMMUNOTHERAPY (2004)
Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease
KG Lucas et al.
CANCER (2004)
The role of cytokines in classical Hodgkin lymphoma
BF Skinnider et al.
BLOOD (2002)
分享论文
